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TemozolomideAbstract Spinal intradural tumors, especially those extending along the entire length of the spinal
cord, termed as ‘holocord’ tumors are uncommon. Most of these are gliomas, with astrocytomas
(low grade) predominating in children and ependymomas in adults. Other histologies, though
reported, are even rarer. Management is debatable, with both surgery and radiotherapy of such
extensive tumors posing challenges. We describe a case of a 14-year-old girl with holocord astrocy-
toma extending from cervicomedullary junction till lumbar spine, who recovered full neurological
function following radical irradiation of entire spine followed by temozolomide-based chemother-
apy. No grade 3/4 bone marrow morbidity was seen. Five years following treatment, she maintained
normal neurological function and apparently normal pubertal and skeletal growth despite residual
disease visible on imaging. Literature review of existing reports of holocord astrocytomas highlight-
ing management and outcome is presented.
ª 2015 The Authors. Production and hosting by Elsevier B.V. on behalf of National Cancer Institute,
Cairo University. This is an open access article under the CC BY-NC-ND license (http://
creativecommons.org/licenses/by-nc-nd/4.0/).Introduction
Intramedullary spinal cord gliomas are uncommon tumors.
Astrocytomas predominate in children while ependymomas
are commoner in adults [1]. Sometimes tumors extend along
extensive lengths of the spinal cord, making surgery as well
as radiotherapy challenging. No large series or guidelines exist
to guide appropriate management in such situations.
We describe the case of a child diagnosed to have a low
grade astrocytoma of spine, which was successfully managedwith radiotherapy and chemotherapy, and regained full neuro-
logic function which was maintained on long term follow up.
Case report
A 14-year-old girl presented to us with progressively worsening
weakness of both lower limbs for 5 months. She also had his-
tory of focal seizures involving both lower limbs for 2 months
and urinary and fecal incontinence for 1 month. There was no
history of headache, nausea or vomiting, trauma or tuberculo-
sis. She had normal developmental history and her two older
siblings were normal. She had menarche at 13 years of age.
She was evaluated by a neurosurgeon.
Magnetic resonance imaging (MRI) of spine showed a cys-
tic intramedullary space occupying lesion extending from C3
to D12–L1 vertebral levels, with multifocal, thick-walled
106 S. Goyal et al.enhancement from D4–5 to D12–L1. MRI brain was normal.
Biopsy showed grade 2 astrocytoma. The case was diagnosed
as a holocord astrocytoma and was referred to us for radical
radiotherapy.
On examination, higher mental functions and cranial nerves
were normal. Power in bilateral upper limbs was 5/5 and in
bilateral lower limbs was 1/5. Sensations were reduced below
the xiphoid. There was fecal and urinary incontinence. The
child was planned for radiotherapy (RT) to whole spine from
C1 to conus medullaris by direct posterior ﬁeld; with cobalt-60
using a conventional simulator. A dose of 45 gray (Gy) in 25
fractions over ﬁve weeks was delivered.
The child tolerated RT well with no grade 3/4 hematologic
or neural toxicities. Three months following RT, power in
bilateral lower limbs had returned to 4+/5. Bladder and bowel
sensations were restored and sensations were also regained.
Repeat MRI spine with contrast performed at 3 months
post-RT showed signiﬁcant residual disease despite the neuro-
logic improvement. Following this, she received six cycles of
chemotherapy with temozolomide 150 mg/m2 orally D1–5
given every 4 weeks. She has been on follow up since then.
Serial MRI examinations have shown a considerable reduction
in the spinal tumor and the child continues to be neurologically
asymptomatic till last follow up at 5 years. Although no speci-
ﬁc tests were performed to establish hormonal function, she
attained apparently normal pubertal growth with resumption
of menstruation after a brief interruption following treatment.Discussion
Pediatric intramedullary tumors comprise 35% of all spinal
tumors, with a predominance of low grade astrocytomas
(LGAs), which constitute 60% of all intramedullary tumors.
Intramedullary low grade spinal astrocytomas (IMLGSA)
have a slight male predominance. Onset is insidious with symp-
toms of pain, or sensory, motor or autonomic dysfunction
depending upon site and extent of involvement. Gait distur-
bances, regression of milestones, torticollis, and kyphoscoliosis
may be other features. MRI is the imaging modality of choice.
Astrocytomas have less well-deﬁned margins and are more
likely to be eccentrically located within the spinal cord, unlike
ependymomas which are always central in location. Unlike
LGAs in the brain, IMLGSA show intense post-contrast
enhancement. At least 50% have cysts which are indistinguish-
able from solid tumors on T2 weighted studies owing to high
protein content, but do not enhance with contrast [1–3]. Loca-
tion is commonly cervicothoracic or thoracic, though most
lesions span over multiple levels. Microscopically, IMLGSA
show a low degree of cellularity, low mitotic activity, and
absence of necrosis and endothelial microvascular prolif-
eration. Pilocytic astrocytomas typically contain Rosenthal
ﬁbres.
Rarely, IMLGSA may extend along long segments extend-
ing from cervicomedullary junction to conus (<1% of intra-
medullary lesions), in which case they are termed holocord
astrocytomas. The ﬁrst report of a holocord tumor was given
by Cushing in 1927, histology being ependymoma [4]. Scant lit-
erature exists on the appropriate management of holocord
tumors. Advancement in MRI technology, neurophysiologic
monitoring, and surgical equipment have greatly enhanced
the ability for safe and effective treatment [5]. Epstein andEpstein ﬁrst described 3 cases, which they managed surgically
using Cavitron Ultrasonic Aspirator (CUSA) without
compromising neurologic function [6]. Benzel et al. described
a two-staged microsurgical technique for complete tumor
removal in 2 patients with LGA. Somatosensory evoked
potential was used as intraoperative monitoring tool. Patients
were disease-free and neurologically better at 4 years and
3 years, respectively [7].
Irikura et al. have detailed 24 cases of holocord tumors
reported till 1990, of which 7 were astrocytomas (mean age
11.3 years, male:female 6:1). Of these, 6 underwent partial
resection with or without shunt insertion and improved post-
operatively, and the management in the seventh case was not
deﬁned [8]. Twelve more cases were added by Schittenhelm
et al. [9]. Mean age of these 19 patients collectively was
9.2 years, with a male:female ratio of 2.6. Surgery details avail-
able for 14 patients showed gross total removal (GTR) in 6,
subtotal resection (STR) in 7 and biopsy in 1 patient. Of these
14 patients, 2 had received preoperative radiotherapy (RT)
with no signiﬁcant beneﬁt, but dose and technique were not
described. Ten patients improved neurologically, 2 were stable
neurologically despite progression on MRI, 1 had progressed
while 1 died. Follow up was available for 9 patients and ranged
from 3 months to 4.5 years (Table 1) [5–18].
Radiotherapy has been used in managing IMLGSA in the
setting of biopsy or partial removal. Robinson et al. reported
on 14 patients with pathologically conﬁrmed IMLGSA (medi-
an extent 2 vertebral widths), with surgery (biopsy 7, STR 6,
GTR 1) and postoperative RT (10 patients). Overall survival
(OS) and progression-free survival (PFS) at 5 years were
100% and 93%, respectively, and bore no correlation with
any patient, tumor, or treatment factors. Postoperative wors-
ening of neurological function and Karnofsky’s performance
status (KPS) was seen in 8 and 9 patients, respectively. At a
median follow up of 10.2 years, neurologic function stabilized
or improved in 8, and KPS worsened in 5 patients. The authors
recommended that patients with limited resection should
receive postoperative RT (50.4 Gy in 1.8-Gy fractions) [19].
Another series of 36 spinal tumors, consisted of 7 LGAs,
which were managed with surgery (biopsy 2, STR 4, GTR 1)
followed by postoperative RT (median dose 45 Gy in 18
fractions); 3 patients received chemotherapy. Three-year
actuarial survival was 80%. Overall, motor function was simi-
lar between those who received RT and those who did not. No
radiation myelopathy was noted at doses up to 50 Gy delivered
at 2.5 Gy per fraction [20]. Minehan and colleagues, in a large
series of 136 IMLGSAs, showed that postoperative RT, deliv-
ered in 75% of these cases, gave no signiﬁcant survival beneﬁt
for those with pilocytic tumors (39.9 vs 18.1 years, p= 0.33)
but had signiﬁcant survival beneﬁt for those with inﬁltrative
astrocytomas (24 vs 3 months; p= 0.006). Pilocytic histologic
type, longer symptom duration, younger age, minimal surgical
extent, and postoperative RT predicted better outcome [21].
Pre- and post-operative clinical status and grade have also
been termed important prognostic factors [22]. Even for larger
tumors with median span of 16 spinal levels (13 patients
including 3 IMLGSA), total resection was achieved in 8 and
subtotal excision in 5 patients. Six patients received radio-
therapy (5 preoperative and 1 postoperative). At a median fol-
low up of 3.4 years, neurologic function improved in 3,
stabilized in 7 and worsened in 2 patients. One patient with
anaplastic oligodendroglioma died from progression [5].
Table 1 Summary of reports of holocord astrocytomas including demographic and treatment characteristics [5–18].
S.No. Author Year Age (years) Sex Sx Shunt RT Result Follow up
1 Lowenberg* 1939 14 Male ? ? ? ? ?
2 Epstein [6] 1981 15 Male STR No No Improved nr
3 5 Male STR No Yes, preop Improved nr
4 4 Female STR No Yes, preop Improved nr
5 Tedeschi [10] 1982 12 Female STR ? ? Improved nr
6 Nikaido [11] 1984 2 Male GTR ? ? Died nr
7 Benzel [7] 1987 23 Male GTR ? ? Improved 4 years
8 2.5 Male GTR ? ? Improved 3 years
9 Irikura [8] 1990 27 Male STR ? ? Improved 9 months
11 Vles [12] 1990 11 Female ? ? ? ? ?
10 Shafrir [13] 1992 4/12 Male ? ? ? ? ?
12 Minehan [14] 1995 nr nr ? ? ? ? ?
13 Lau [15] 1998 4/12 Male ? ? ? ? ?
14 Chacko [16] 2000 14 Male GTR No No Improved 3 months
15 Sandalcioglu [17] 2002 4/12 Male STR Yes No Neurologically stable,
progression on MRI
4.5 years
16 Komotar [18] 2005 1/12 Male Biopsy Yes No Neurologically stable,
progression on MRI
3.5 years
17 Tobias [5] 2008 13 Male GTR No No Improved 31 months
18 11 Female GTR No No Improved 20 months
19 Schittenhelm [9] 2009 13 Female STR Yes No Progression 8 months
20 Goyal (present case) 14 Female Biopsy No No Neurological improvement,
residual disease on MRI
5 years
GTR: gross total resection; MRI: magnetic resonance imaging; nr: not reported; preop: preoperative; RT: Radiotherapy; STR: subtotal
resection; ?: unknown.
* Cited by Tanaka H, Shimizu H, Ishijima B, Nakamura Y (1986) Myxopapillary ependymoma of the ﬁlum terminale with a holocord cyst: A
case report. No Shinkei Geka 14:997–1003 (in Japanese).
Radiotherapy in holocord glioma 107To our knowledge, radiotherapy alone or following biopsy
has never been reported in holocord astrocytomas prior to this
report. Also, the role of temozolomide-based chemotherapy is
evolving in very young children in an effort to delay radiation,
but their role in residual IMLGSA has been largely unexplored
[23]. Our experience shows that whole spine radiotherapy to
doses to 45 Gy along with chemotherapy is safe and effective,
as evidenced by the complete neurological recovery despite
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